Macbee Planet (7095) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
24 Jul, 2025Executive summary
Sales and revenue more than doubled year-over-year, reaching ¥39,405 million, surpassing medium-term plan targets and laying groundwork for future expansion.
Growth was driven by the acquisition and consolidation of All Ads, organic expansion at MAVEL, and robust new/expanded contracts in LTV Marketing.
Strategic initiatives included PR firm acquisition, shift to next-gen internet advertising, increased M&A activity, and transition to a holding company structure.
Net assets increased by ¥1,863 million year-over-year, reflecting strong profit and capital increases despite dividend and share buyback outflows.
Completed a public offering and 4-for-1 stock split to strengthen the financial base and broaden the investor base.
Financial highlights
FY4/24 sales reached ¥39,405mn, up 101% year-over-year; EBITDA rose 112% to ¥4,904mn; operating profit increased 104% to ¥4,418mn; OP margin improved to 11.2%.
Net income rose 45.7% to ¥2,282mn; EPS increased to ¥158.77 from ¥120.55.
Q4 sales grew 88% year-over-year and 4% sequentially, with strong performance in finance, medical, and human talent sectors.
Cash and equivalents at year-end: ¥11,327mn, up ¥1,664mn from prior year.
Gross profit per consultant and annual revenue per customer both improved post-consolidation.
Outlook and guidance
FY4/25 sales forecast at ¥48,000mn (+21.8% YoY); operating profit projected at ¥4,500–5,000mn (+23–36% YoY); net income expected ¥2,720–3,070mn (+19.1–34.5% YoY).
Medium-term plan targets 20–30% annual sales and profit growth, excluding major M&A.
Up to ¥0.5bn to be invested in PR to boost awareness and recruitment.
Latest events from Macbee Planet
- Revenue and profit fell sharply year-over-year, but full-year guidance is maintained.7095
Q3 202613 Mar 2026 - Operating profit and margin fell as revenue growth slowed, leading to a downward forecast revision.7095
Q2 202611 Dec 2025 - Q1 revenue up 11% year-over-year, but profit fell sharply on higher ad costs; recovery forecast.7095
Q1 202611 Sep 2025 - Record sales and profit growth, led by medical and LTV Marketing, with a major share buyback.7095
Q1 202524 Jul 2025 - Sales up 30% in 1H, with strong growth in medical, finance, and LTV Marketing.7095
Q2 202524 Jul 2025 - Net sales and profits rose sharply, with upgraded guidance and strong LTV Marketing growth.7095
Q3 202524 Jul 2025 - Record sales and profit growth, with strong FY2026 outlook and expanded shareholder returns.7095
Q4 202524 Jul 2025